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Abstract
A correlation between increase in the integration of Human Immunodeficiency virus-1 (HIV-1) cDNA and cell death
was previously established. Here we show that combination of peptides that stimulate integration together with
the protease inhibitor Ro 31-8959 caused apoptotic cell death of HIV infected cells with total extermination of the
virus. This combination did not have any effect on non-infected cells. Thus it appears that cell death is promoted
only in the infected cells. It is our view that the results described in this work suggest a novel approach to specifi-
cally promote death of HIV-1 infected cells and thus may eventually be developed into a new and general
anti-viral therapy.
Findings
No cure or vaccine are currently available for the
human immunodeficiency virus type 1 (HIV-1) infection
as well as for the resulting Acquired Immunodeficiency
syndrome (AIDS) [1]. However, an highly active antire-
troviral therapy (HAART), which blocks the activities of
the viral reverse transcriptase and protease and inhibits
the virus-host fusion process, is presently used [2,3].
The HAART transforms the infection process into a
chronic disease [4-6]. Furthermore, the risk of infection
can significantly be reduced if the HAART treatment is
given right after exposure to the virus [7].
New therapeutic approaches and new anti-viral inhibi-
tors are being continuously developed to obtain a better
restriction of the HIV-1 infection process [8-19]. How-
ever, once the viral cDNA is integrated into the host
chromosome it is almost impossible to terminate infec-
tion process and cure AIDS. A way to eradicate the
integrated viral cDNA from virus infected cells by sti-
mulating the viral Integrase (IN) mediated disintegration
process was suggested recently [20,21]. However, this
approach is only in its initial steps [20].
HIV-1 infected cells, unlike cells infected by other ret-
roviruses, bear only 1-2 copies of integrated viral
cDNA/cell [22,23]. This is in spite of the presence of
numerous copies of unintegrated viral cDNA [22,24].
Recently we have shown that this restriction is due to
inhibition of the viral IN activity as well as of its nuclear
import by an early expressed viral Rev protein following
Rev-IN interaction [25-30]. Disruption of the Rev-IN
complex by IN-derived cell permeable peptides, such as
the INS [31] and INrs [28], results in multi-integration
of the viral cDNA [26,28,31]. Previous findings have
shown that multi-integration of viral DNA in AIDS
patients may lead to host genome instability [32].
Indeed, a correlation between promotion of multi-inte-
gration and increase in cell death was demonstrated
recently by us [25].
Based on these observations we have developed a
novel approach to specifically and significantly eradicate
HIV-1 infected cells as well as to eliminate infectious
virions from cultured cells. As can be seen in Fig. 1a,
addition of the integration-stimulating INS or INr pep-
tides or combination of both (150 μM each) to cells
infected by wild type (WT) HIV-1 significantly increased
the appearance of new virions during the first 6-8 days
post infection (PI). However, from the eighth day PI, a
decrease in virus production can be observed. The
results in Fig. 1b show that the degree of the reduction
is directly correlated to the MOI (multiplicity of infec-
tion) of the infected HIV-1. Almost complete eradica-
tion of virions was obtained when cells were infected, in
the presence of the INS and the INr peptides, by rela-
tively high titer of the virus (Fig. 1b). This eradication
(Fig. 1a and 1b) is probably due to promotion of cell
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death (Fig. 1c), which in turn may result from the pep-
tides induced stimulation of the integration process (Fig.
1dI and see [28]). Our results indicate that at very long
periods PI a complete eradication of virus particles is
obtained (Fig. 1).
When the specific HIV-1 protease inhibitor (Ro 31-
8959 [33]) was added to virus infected cells together
with either the INS or the INrs peptides or with both
(the mixture of the INS, INrs and Ro 31-8959 was
designated as Mix, see Fig. 1) the increase in virus pro-
duction (Fig. 1a) and in viral cDNA integration (Fig.
1dII) was observed only during the first 2-4 days PI. On
the other hand a drastic reduction in both virus produc-
tion and cDNA integration could be observed from the
fourth day PI and on, reaching below the detection
levels in the presence of the Mix (Fig. 1a and 1dII). As
Figure 1 Specific killing of HIV-1 infected cells. (a) H9 lymphocyte T cells were infected by the WT HIV-1 at MOI of 0.1, exactly as described
in [28], and then the infected cells were treated every two days with the indicated molecules or combinations. Every two days a sample was
removed and its virus titer was estimated by the MAGI assay [37] using TZM-bl cells exactly as described [28]. (b) H9 lymphocyte T cells were
infected with WT HIV-1 at the indicated MOIs and treated with INS or INS+INrs. The amount of virus production was estimated using MAGI assay
on TZM-bl cells at 48 h PI. (c) Same as (a) but cells viability was estimated by the MTT assay as described in [28]. (dI) and (dII) Same as (a) but
the average amount of viral cDNA integration events/cells was estimated by quantitative hemi-nested Real Time PCR exactly as described in [28].
Cells were grown as described in [28]. Viruses were produced and viral stock titer was estimated as described in [29]. Peptides were synthesized
and purified as described in [28,31]. The following concentrations were used: AZT 2 μM, Ro 31-8959 10 nM, INS/INrs 150 μM. Every experiment
was preformed at least three times with relative error not more ±10%. Error bars represent standard deviation.
Levin et al. AIDS Research and Therapy 2010, 7:31
http://www.aidsrestherapy.com/content/7/1/31
Page 2 of 5
can be seen (Fig. 1c) about 40% of the cultured cells
died by the eighth day PI following the addition of the
Mix. This percentage may represent the relative amount
of virus infected cells, probably indicating total death of
these cells. Furthermore, our results (Fig. 1a and 1dII)
clearly show that at this time (8 days PI) the large
majority of the virus was cleared from the culture.
Therefore it is conceivable that the increase in the
percentage of viable cells observed between 8-12 days PI
(Fig. 1c) is due to division of uninfected cells.
To determine whether the above treatment (combina-
tion of INS + INrs and Ro 31-8959) indeed results in
eradication of the infected virions and termination of
the infection process, the following experiment was con-
ducted: the cultured cells were infected by the WT HIV
at MOI of 1 and 24 h PI cells were treated, every two
Figure 2 Eradication of HIV-1 infection. H9 lymphocyte T cells were infected with the WT HIV-1 at MOI of 1, exactly as described in [28].
Starting at 24 h PI the infected cells were treated every two days with the indicated molecules for two weeks. At the end of the two weeks
treatment, cells were left to grow untreated. (a) The average amount of viral RNA copies per cell was estimated as described in [38]: prior to
treatment, at the end of the two weeks treatments and two weeks post the termination of the treatment (four weeks PI). (b) Same as in (a) but
the average amount of viral DNA copies per cell was estimated as described in [29,39]. (c) Same as in (a) but the average amount of integration
events per cells was estimated as described in [28]. (d) Same as in (a) but the average amount of viral p24 was estimated as described in [30](e)
The amount of infectious virus produced by the cells was estimated, as described in [28]. All other conditions ad described in Fig. 1.
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days, with Ro 31-8959, INS+Ro 31-8959, INrs+Ro 31-
8959 or by the Mix for the total duration of two weeks.
Following this period the treated cells were left to grow,
untreated, for two additional weeks.
At the end of each of those periods namely: pre treat-
ment, after two weeks of treatment and two weeks post
termination of treatment (four weeks PI), the average
amounts of viral RNA copies/cell (Fig. 2a), total viral
DNA copies/cells (Fig. 2b) and of integrated viral
cDNA/cell (Fig. 2c) as well as the amounts of viral p24
protein (Fig. 2d) and appearance of new virions (Fig. 2e)
were estimated.
As can be seen a substantial reduction in virus pro-
duction and integration was observed following the first
two weeks treatment (Fig. 2), However, when treatment
with the various combinations of peptides and the pro-
tease inhibitor was terminated, virus production and
integration were restored except in cells treated with the
Mix, indicating a Mix induced complete eradication of
infection (Fig. 2).
It appears that the INS and INrs induced cells death is
mostly by a caspase 3-dependent apoptosis pathway. This
can be inferred from the western blot analysis which
shows the appearance of active caspase 3 (apoptosis mar-
ker [34]) (Fig. 3). On the other hand, no autophagy cell
death or necrosis could be observed following western
blot analysis using the anti apg16 (autophagy marker [35])
or TNF a (necrosis marker [36]) respectively (Fig. 3). As
expected–and also observed in Fig. 2d–a western blot ana-
lysis also show that there is reduction in the production of
p24 in cells treated by the protease inhibitor Ro 31-8959
(Fig. 3). In addition both INS and INrs peptides which sti-
mulate integration and infection also stimulated produc-
tion of p24 (Fig. 3 and see also [28,31]). This increase in
infection is in direct correlation to apoptotic cell death
(Fig. 3 and see also [28,31]). On the other hand, when Ro
31-8959 was added together with INS, INrs or both, a sig-
nificant decrease in p24 as well as increase in apoptotic
cell death could be observed (Fig. 3).
It should be noted that the possibility in which a low
number integrated viral DNA is still be present at a
latent state cannot be totally excluded. Further experi-
ments are presently being conducted in our laboratory
in order to study reactivation of those few– if any–latent
proviruses.
We conclude that stimulation of viral integration by
the INS and INrs peptides, combined with the preven-
tion of virion production by the protease inhibitor, not
only resulted in blocking of HIV-1 infection but also in
extermination of the infected cells by invoking apopto-
sis. This treatment has cleared the cell culture from
cells bearing the integrated proviruses. It should be
added however that the novel approach described here
for AIDS therapy is only in its initial steps and further
attempts to improve the activity of the stimulating
peptides are currently conducted in our laboratory.
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